<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3941">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055611</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.HAEM89-002</org_study_id>
    <nct_id>NCT03055611</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elocta (rFVIIIFc) and Alprolix (rFIXFc) are recombinant extended half-life coagulation
      factor products. The purpose of this non-interventional study is to describe the real-world
      usage and effectiveness of Elocta and Alprolix in the prophylactic treatment of haemophilia
      A and B.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annualised bleeding rate (ABR)</measure>
    <time_frame>24 months</time_frame>
    <description>Based on bleeding episodes assessed by local practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualised injection frequency</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by prescription</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualised factor consumption (IU)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by dispensed factor product</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>Haemophilia A patients</arm_group_label>
    <description>Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haemophilia B patients</arm_group_label>
    <description>Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELOCTA</intervention_name>
    <description>Extended half-life factor VIII product</description>
    <arm_group_label>Haemophilia A patients</arm_group_label>
    <other_name>Eloctate, efmoroctocog alfa, rFVIIFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALPROLIX</intervention_name>
    <description>Extended half-life factor IX product</description>
    <arm_group_label>Haemophilia B patients</arm_group_label>
    <other_name>Eftrenonacog alfa, rFIXFc</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible Elocta and Alprolix patients who present for a routine Clinical visit will be
        asked to participate in the study by the treating physician at participating haemophilia
        treatment centres in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of haemophilia A or B and previously treated with factor Product

          -  Have started prophylactic Elocta/Alprolix treatment within 3 months prior to
             enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or
             Alprolix regardless of participation in the study

          -  Signed and dated informed consent provided by the patient, or the patient's legally
             acceptable representative for patients under the legal age, Before any study-related
             activities are undertaken. Assent should be obtained from paediatric patients
             according to local regulations.

        Exclusion Criteria:

          -  Enrollment in concurrent Clinical interventional study involving intake of an
             investigational Product (IMP), within Three months prior to enrollment visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bent Winding, MD</last_name>
    <role>Study Director</role>
    <affiliation>Swedish Orphan Biovitrum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael O'Malley</last_name>
    <phone>+46 8 697 2000</phone>
    <email>michael.omalley@sobi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sofia Bergenstråle</last_name>
    <phone>+46 8 697 2000</phone>
    <email>sofia.bergenstrale@sobi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MVZ Gerinnungszentrum Hochtaunus</name>
      <address>
        <city>Bad Homburg</city>
        <zip>61325</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa Sonja Alesci, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité-universitätsmedizin Berlin, Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Holzhauer, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Braunschweig, Hämophilieambulanz</name>
      <address>
        <city>Braunschweig</city>
        <zip>38118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Eberl, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School, Clinic for Haematology, Oncology and stam cell transplantation</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Tiede, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für Blutgerinnungsstörungen MVZ Labor Dr Reising-Ackermann und Kollegen</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ute Scholz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DKD Helios Klinik Wiesbaden Gmbh</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuela Krause, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>February 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Coagulation Disorder</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Coagulation Protein Disorder</keyword>
  <keyword>Hemorrhagic Disorder</keyword>
  <keyword>Genetic Diseases, Inborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
